All In Biotech

Drug Trial Radar · NCT02699086

A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)

A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD), Part I

Last checked: Nov 20, 2026Latest source record: Dec 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

6

Actual

Start

Dec 1, 2019

Primary completion

Jul 15, 2020

Study completion Jul 15, 2020

Sponsor

Lead sponsor
BioLite, Inc.Industry
Sponsor type
Industry
First posted
Mar 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial was to determine the effective doses and treatment period of PDC-1421 Capsule in subjects with ADHD. The secondary objective was to evaluate the safety of PDC-1421 Capsule in subjects receiving PDC-1421 at various dose levels.

Conditions

  • Attention-Deficit Hyperactivity Disorder (ADHD)

Interventions

  • PDC-1421 CapsuleDrug

    PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Improvement ≥ 40% in ADHD-RS-IV From Baseline up to 8 Weeks TreatmentTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCSF Medical Center

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.